LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 23rd Annual Needham Virtual Healthcare Conference at 8:00am ET on April 9, 2024.
A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following such event. For more information, please visit investor section of compasspathways.com.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP 360 psilocybin therapy in TRD, the largest randomized, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. Compass is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing. .
Availability of other information about Compass Pathways
Investors and others should note that we communicate with our investors and the public using our website (), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including, but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Enquiries
Media: Amy Lawrence, amy@compasspathways.com, +44 7813 777 919
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
伦敦,2024年4月1日(GLOBE NEWSWIRE)——致力于加快患者获得心理健康循证创新的生物技术公司Compass Pathways plc(纳斯达克股票代码:CMPS)今天宣布,管理层将出席第23届会议第三方 年度尼德姆虚拟医疗保健会议将于美国东部时间2024年4月9日上午8点举行。
该演示文稿的网络直播可从Compass网站 “投资者” 部分的 “活动” 页面上观看。网络直播的重播将在此类活动结束后的30天内开放。欲了解更多信息,请访问compasspathways.com的投资者专区。
关于指南针路径
Compass Pathways plc(纳斯达克股票代码:CMPS)是一家生物技术公司,致力于加速患者获得心理健康领域的循证创新。我们的重点是改善那些面临心理健康挑战且没有得到当前治疗帮助的人的生活。我们正在率先开发一种新的迷幻药疗法,在该模式中,我们的专有合成迷幻药配方 COMP360 与心理支持一起使用。COMP360 已被美国食品药品监督管理局 (FDA) 指定为突破性疗法,并已在英国获得耐药性抑郁症 (TRD) 创新许可和准入途径 (ILAP) 称号。我们已经在TRD启动了COMP 360迷幻药疗法的3期临床计划,这是有史以来最大的随机、对照、双盲迷幻药疗法临床项目。此前,我们完成了一项2b期研究,顶线数据显示,接受单剂量25mg COMP360 psilocybin和心理支持的患者在三周后,抑郁症状严重程度在统计学上显著(p<0.001)且具有临床相关性的改善。我们还在进行创伤后应激障碍(PTSD)和神经性厌食症的 COMP360 迷幻药疗法的二期临床研究。Compass总部位于英国伦敦,在美国纽约和旧金山设有办事处。我们的愿景是一个心理健康的世界。
有关指南针路径的其他信息的可用性
投资者和其他人应注意,我们使用我们的网站 ()、我们的投资者关系网站(ir.compasspathways.com)和社交媒体(LinkedIn)与投资者和公众进行沟通,包括但不限于投资者介绍和投资者情况说明书、美国证券交易委员会文件、新闻稿、公开电话会议和网络直播。我们在这些频道和网站上发布的信息可能被视为重要信息。因此,我们鼓励投资者、媒体和其他对我们感兴趣的人定期查看这些渠道(包括投资者关系网站)上发布的信息。此渠道清单可能会在我们的投资者关系网站上不时更新,并可能包括其他社交媒体渠道。根据1933年《证券法》提交的任何文件中,我们网站或这些渠道的内容,或可能通过我们的网站或这些渠道访问的任何其他网站的内容,均不应被视为以引用方式纳入其中。
查询
媒体:艾米·劳伦斯,amy@compasspathways.com,+44 7813 777 919
投资者:斯蒂芬·舒尔茨,stephen.schultz@compasspathways.com,+1 401 290 7324